Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/2/2015)... July 2, 2015 According to a ... (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application ... Forecast to 2020", published by MarketsandMarkets, the global Neuromodulation Market ... to reach $6.20 Billion by 2020, at a CAGR of ... 8 4 market data T ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
(Date:7/2/2015)... , June 25, 2015 ... has announced the addition of the ... Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in Clinical Chemistry and ... is a new seven-country strategic analysis of ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
... - Results Presented at ASH Annual Meeting- , ... Sanofi-aventis today announced results of a randomized phase ... the American Society of Hematology. The study in adult ... for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) ...
Cached Medicine Technology:Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/3/2015)... LENEXA, Kan. (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits ... Cancer Lawsuit Center website. Just as the previous version did, the new website will ... lawsuit updates and ovarian cancer warning information. The site is routinely updated with news ...
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and expose popular lies regarding proper relationships according to the bible. , ... the core of the subject by explaining why certain types of sexual relationships are ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking ... the University of Minnesota, they knew it would save the university energy and ... award-winning choice: the total energy savings after installation was an impressive 89 percent, ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... TAMPA, Fla., May 13 A complete review ... of a multi-disciplinary and,collaborative approach to weight loss, ... Clinics(R). The use of several proven,weight management strategies ... offer the greatest likelihood of success., NBC,s ...
... Performance during Sports or Play, CARLSBAD, Calif., May ... and retailer of custom-fitted arch supports and,natural sponge rubber ... of arch supports designed specifically for children ages 6 ... "SportFlex," are now,currently available at participating Good Feet Stores ...
... Israel, May 13 Lumenis Inc., a ... and radiofrequency,devices for surgical, aesthetic, and ophthalmic ... Laser Enucleation of the Prostate (HoLEP),preceptor program ... are interested in learning and performing HoLEP. ...
... 2008 Johnson & Johnson today announced that Professor ... Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy ... the recipients of the 2008 Dr. Paul Janssen Award ... world-renowned scientists. , The award salutes the most ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
Cached Medicine News:Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 2Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4
Inquire...
Inquire...
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
... a new device for skin extension.Thanks to ... strips, it allows a constant and powerful ... other devices capacities. Such effectiveness makes the ... it is removed before 30 days. Furthermore ...
Medicine Products: